Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
samatatatug zovodotin
- Development stage
- Phase 1
- Lead developer
- Exelixis
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Samatatatug zovodotin (XB002) is a next-generation antibody-drug conjugate (ADC) targeting Tissue Factor (TF), also known as coagulation factor III. It is composed of a human monoclonal antibody (samatatatug) conjugated to a potent cytotoxic payload, zovodotin (an auristatin derivative), via a protease-cleavable linker. The drug is designed to bind to TF on the surface of tumor cells, leading to internalization and the subsequent release of the payload, which inhibits microtubule polymerization and induces apoptosis. Notably, samatatatug zovodotin is engineered to bind TF without interfering with the coagulation cascade, a design intended to improve the safety profile regarding bleeding compared to earlier TF-targeting ADCs. It is currently being evaluated in Phase 1 clinical trials for the treatment of various advanced solid tumors, including cervical, ovarian, and lung cancers.
- Other names
- samatatatug zovodotinXB002XB-002XB 002
02
Targets
F3 (Tissue factor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on samatatatug zovodotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on samatatatug zovodotin.